Open AccessEGFR-TKI plus brain radiotherapy versus EGFR-TKI alone in the management of EGFR-mutated NSCLC patients with brain metastases
Author(s) -
Kai Dong,
Wenhua Liang,
Shen Zhao,
Minzhang Guo,
Qihua He,
Caichen Li,
Haiqing Song,
Jianxing He,
Xiaojun Xia
Publication year - 2019
Publication title -
translational lung cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 41
eISSN - 2226-4477
pISSN - 2218-6751
DOI - 10.21037/tlcr.2019.06.12
Subject(s) - medicine , brain metastasis , oncology , hazard ratio , subgroup analysis , epidermal growth factor receptor , lung cancer , erlotinib , population , proportional hazards model , tyrosine kinase inhibitor , meta analysis , cancer , metastasis , confidence interval , environmental health
It has been confirmed that epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) presented better efficacy than brain radiotherapy (brain RT) in the treatment of brain metastasis (BM) in EGFR mutated NSCLC patients. However, whether the combination of EGFR-TKIs and brain RT is better than EGFR-TKIs alone remains unclear. We aim to compare the outcomes of adding brain RT to EGFR-TKIs and to screen for the beneficial population by a meta-analysis of currently available data.